Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Abbott (ABT) is projected to report Q2 EPS of $1.25, a 9.7% increase year-over-year, and revenues of $11.07 billion, up 6.7%, despite a recent 0.4% downward revision in the consensus EPS estimate. Analysts anticipate robust segment growth, particularly in Medical Devices, with Diabetes Care sales expected to surge 17.5% to $1.94 billion and U.S. Structural Heart sales rising 17.9% to $304.28 million. While ABT shares have declined 2.7% in the past month against the S&P 500's 4% gain, the stock holds a Zacks Rank #2 (Buy), indicating expected near-term market outperformance.

Analysis

Abbott Laboratories is approaching its Q2 earnings report with analyst expectations set for significant year-over-year growth, forecasting a 9.7% increase in EPS to $1.25 and a 6.7% rise in revenue to $11.07 billion. However, a minor downward revision of 0.4% to the consensus EPS estimate over the past 30 days suggests a slight tempering of analyst optimism. The primary growth engine is anticipated to be the Medical Devices segment, with standout projections for Diabetes Care sales to surge 17.5% to $1.94 billion and U.S. Structural Heart sales to grow 17.9% to $304.28 million. In contrast, the Diagnostics division is expected to post minimal growth of 1.0%, reflecting a continued normalization from pandemic-driven demand. Other segments like Nutrition and Established Pharmaceuticals are projected to deliver solid, mid-single-digit growth of 4.3% and 6.1%, respectively. Despite these strong underlying forecasts and a Zacks Rank #2 (Buy), Abbott's stock has underperformed, declining 2.7% in the past month while the S&P 500 composite gained 4.0%, indicating a potential disconnect between market sentiment and fundamental expectations.

Key Decisions for Investors

• Given the strong growth forecasts in key segments like Medical Devices, investors may consider the recent -2.7% stock price decline as a potential entry point ahead of earnings, especially with a supportive Zacks #2 (Buy) rating.
• Pay close attention to the performance of the Diabetes Care and Structural Heart divisions, as their high-growth expectations (+17.5% and +17.9% respectively) represent a high bar that must be met or exceeded to validate the bullish thesis.
• Scrutinize the company's forward guidance closely, as the modest downward EPS revision and sluggish growth in Diagnostics (+1.0%) could signal underlying margin pressures or a weaker-than-expected outlook in certain areas.